- Home
- IQV vs DXCM Comparison
IQV vs DXCM Comparison
Compare IQV & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQV
- DXCM
- Stock Information
- Founded
- IQV 1982
- DXCM 1999
- Country
- IQV United States
- DXCM United States
- Employees
- IQV N/A
- DXCM N/A
- Industry
- IQV Biotechnology: Commercial Physical & Biological Resarch
- DXCM Medical/Dental Instruments
- Sector
- IQV Health Care
- DXCM Health Care
- Exchange
- IQV Nasdaq
- DXCM Nasdaq
- Market Cap
- IQV 31.0B
- DXCM 31.7B
- IPO Year
- IQV 2013
- DXCM 2005
- Fundamental
- Price
- IQV $190.28
- DXCM $75.34
- Analyst Decision
- IQV Strong Buy
- DXCM Strong Buy
- Analyst Count
- IQV 19
- DXCM 20
- Target Price
- IQV $229.37
- DXCM $99.90
- AVG Volume (30 Days)
- IQV 1.2M
- DXCM 4.0M
- Earning Date
- IQV 07-22-2025
- DXCM 10-23-2025
- Dividend Yield
- IQV N/A
- DXCM N/A
- EPS Growth
- IQV N/A
- DXCM N/A
- EPS
- IQV 6.92
- DXCM 1.43
- Revenue
- IQV $15,700,000,000.00
- DXCM $4,300,800,000.00
- Revenue This Year
- IQV $6.01
- DXCM $17.03
- Revenue Next Year
- IQV $5.05
- DXCM $15.59
- P/E Ratio
- IQV $27.56
- DXCM $52.68
- Revenue Growth
- IQV 3.60
- DXCM 9.30
- 52 Week Low
- IQV $134.65
- DXCM $57.52
- 52 Week High
- IQV $252.88
- DXCM $93.25
- Technical
- Relative Strength Index (RSI)
- IQV 56.25
- DXCM 36.42
- Support Level
- IQV $185.38
- DXCM $74.21
- Resistance Level
- IQV $193.23
- DXCM $76.97
- Average True Range (ATR)
- IQV 4.03
- DXCM 2.02
- MACD
- IQV -0.87
- DXCM -0.40
- Stochastic Oscillator
- IQV 56.89
- DXCM 13.86
About IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.